Emerging therapies and challenges in spinal muscular atrophy

Area of Science:

• Neurology
• Genetics
• Neurodegenerative Diseases

Background:

• Spinal muscular atrophy (SMA) is a hereditary neurodegenerative disorder with a wide spectrum of clinical severity.
• Current treatments for SMA are limited, leading to significant impacts on patients and families.

Purpose of the Study:

• To summarize the progress in understanding SMA's molecular basis and pathogenesis.
• To review novel therapeutic strategies in development for SMA.
• To discuss the anticipated transformation of the SMA treatment landscape.

Main Methods:

• Review of current literature on SMA molecular basis, pathogenesis, and natural history.
• Appraisal of therapeutic strategies including gene replacement, transcript modulation, neuroprotection, and peripheral targets.
• Consideration of challenges and controversies in implementing novel therapies.

Main Results:

• Significant progress has been made in understanding SMA, leading to novel therapeutic strategies.
• Therapeutic approaches include SMN1 gene replacement, SMN2 modulation, neuroprotection, and targeting peripheral sites like muscle.
• Preliminary trial data suggest a significant transformation in the SMA treatment landscape is imminent.

Conclusions:

• Advancements in understanding SMA pathogenesis and developing novel therapies are poised to revolutionize treatment.
• Presymptomatic diagnosis through newborn screening is crucial for early intervention.
• Long-term monitoring, evaluation of combination treatments, and improved supportive care are essential for managing novel therapies.